UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that ...
Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache. Emgality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback